

BIBLIOGRAPHY

Link to all publications in full text:

https://boris.unibe.ch/view/contributors_bern/Fuster=3ADaniel_Guido=3A=3A.html

Original articles

1. **Fuster D**, Escher G, Vogt B, Ackermann D, Dick B, Frey BM, Frey FJ. Furosemide inhibits 11 β -hydroxysteroid dehydrogenase type 2. *Endocrinology*. 1998;139(9): 3849-54.
2. Klisic J, Hu MC, Nief V, Reyes L, **Fuster D**, Moe OW, Ambühl PM. Insulin activates sodium/hydrogen exchanger NHE3: biphasic response and glucocorticoid dependence. *Am J Physiol Renal Physiol*. 2002;283(3):F532-9.
3. **Fuster D**, Moe OW, Hilgemann DW. Lipid- and mechanosensitivities of sodium/hydrogen exchangers analyzed by electrical methods. *Proc Natl Acad Sci U S A*. 2004;101(28):10482-7.
4. **Fuster D**, Bobulescu A, Zhang J, Wade J, Moe OW. Characterization of the regulation of renal sodium/hydrogen exchanger NHE3 by insulin. *Am J Physiol Renal Physiol*. 2007;292(2):F577-85.
5. **Fuster D**, Zhang J, Xie X.-S., Moe OW. The vacuolar-ATPase B1 subunit in distal tubular acidosis: novel mutations and mechanisms for dysfunction. *Kidney Int*. 2008;73(10):1151-8.
6. Gisler SM, Kittanakom S, **Fuster D**, Wong V, Bertic M, Radanovic T, Hall RA, Murer H, Biber J, Markovich D, Moe OW, Stagljar I. Monitoring protein-protein interactions between the mammalian renal epithelial integral membrane proteins and their PDZ interacting partners using the type II split ubiquitin membrane yeast two-hybrid system. *Mol Cell Proteomics*. 2008;7(7):1362-77.
7. **Fuster D**, Zhang J, Shi M, Bobulescu A, Andersson S, Moe OW. NHA2: An unusual sodium/hydrogen exchanger in renal distal tubules. *J Am Soc Nephrol*. 2008;19(8):1547-56.
8. **Fuster D**, Moe OW, Hilgemann DW. Steady-state function of the ubiquitous mammalian Na/H exchanger (NHE1) in relation to dimer coupling models with 2Na/2H stoichiometry. *J Gen Physiol*. 2008;132(4):465-80.
9. Reining S, Gisler S, **Fuster D**, Moe OW, O'Sullivan G, Betz H, Biber J, Murer H, Hernando N. Gabarap deficiency modulates the expression of NaPi-IIa in renal brush border membranes. *Am J Physiol Renal Physiol*. 2009;296(5):F1118-28.
10. Bobulescu IA, Quinones H, Gisler SM, DiSole F, Shi M, Hu M, Zhang J, **Fuster D**, Wright N, Mumby M, Moe OW. Acute Regulation of Renal Na⁺/H⁺ Exchanger NHE3 by Dopamine: Role of Protein Phosphatase 2A. *Am J Physiol Renal Physiol*. 2010;298:F1205-1213.
11. Hofstetter W, Siegrist M, Simonin A, Bonny O, **Fuster D**. Sodium/hydrogen exchanger NHA2 in osteoclasts: Subcellular localization and role *in vitro* and *in vivo*. *Bone*. 2010;47:331-340.
12. Simonin A, **Fuster D**. Nedd4-1 and β -arrestin-1 are key regulators of Na⁺/H⁺ exchanger 1 ubiquitylation, endocytosis and function. *J Biol Chem*. 2010;285(49):38293-303.

13. Deisl C, Simonin A, Anderegg M, Albano G, Kovacs G, Ackermann D, Moch H, Dolci W, Thorens B, Hediger M and **Fuster DG**. The sodium/hydrogen exchanger NHA2 is critical for insulin secretion in β -cells.
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):10004-9.
14. Rexhaj E, Paoloni-Giacobino A, Rimoldi SF, **Fuster DG**, Anderegg M, Somm E, Bouillet E, Allemann Y, Sartori C, Scherrer U.
J Clin Invest. 2013;123(12):5052-60.
15. Zhang J, **Fuster DG**, Cameron MA, Quiñones H, Griffith C, Xie XS, Moe OW. Incomplete distal renal tubular acidosis from a heterozygous mutation of the V-ATPase B1 subunit.
Am J Physiol Renal Physiol. 2014;307(9):F1063-71.
16. Albano G, Moor M, Dolder S, Siegrist M, Wagner CA, Biber J, Hernando N, Hofstetter W, **Fuster DG**. Sodium-dependent phosphate transporters in osteoclast differentiation and function.
PLoS One. 2015;10(4):e0125104.
17. Dhayat N, Simonin A, Anderegg M, Pathare G, Lüscher BP, Deisl C, Albano G, Mordasini D, Hediger MA, Surbek DV, Vogt B, Sass JO, Kloeckener-Gruissem B, **Fuster DG**. Mutation in the Monocarboxylate Transporter 12 Gene Affects Guanidinoacetate Excretion but Does Not Cause Glucosuria.
J Am Soc Nephrol. 2016;27(5):1426-36.
18. Dhayat N, Schaller A, Albano A, Poindexter J, Griffith C, Pasch A, Gallati S, Vogt B, Moe OW, **Fuster DG**. The vacuolar H⁺-ATPase B1 subunit polymorphism p.E161 is associated with impaired urinary acidification in recurrent stone formers.
J Am Soc Nephrol. 2016;27(5):1544-54.
19. Dhayat NA, Ackermann D, Pruijm B, Ponte B, Ehret G, Guessous I, Leichtle AB, Paccaud F, Mohaupt M, Fiedler GM, Devuyst O, Pechère-Bertschi A, Burnier M, Martin PY, Bochud M, Vogt B, **Fuster DG**. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function
Kidney Int. 2016;90(3):648-57.
20. Deisl C, Anderegg M, Albano G, Lüscher B, Cerny D, Soria R, Bouillet E, Rimoldi S, Scherrer U, **Fuster DG**. Loss of sodium/hydrogen exchanger NHA2 exacerbates obesity- and aging-induced glucose intolerance in mice.
PLoS One. 2016;11(9):e0163568.
21. Albano G, Dolder S, Siegrist M, Mercier-Zuber A, Auberson M, Stoudmann C, Hofstetter W, Bonny O, **Fuster DG**. Increased bone resorption by osteoclast-specific deletion of the sodium/calcium exchanger isoform 1 (NCX1).
Pflugers Arch. 2017;469(2):225-233.
22. Wnuk M, Anderegg M, Graber WA, Buergy R, **Fuster DG**, Djonov V. Neuropilin1 regulates glomerular function and basement membrane composition in mouse kidney.
Kidney Int. 2017;91(4):868-879.
23. Dhayat NA, Gradwell MW, Pathare G, Anderegg M, Schneider L, Luethi D, Mattmann C, Moe OW, Vogt B, **Fuster DG**. Furosemide/Fludrocortisone test and clinical parameters to diagnose incomplete distal renal tubular acidosis in kidney stone formers.
Clin J Am Soc Nephrol. 2017;12(9):1507-1517.
24. Pathare G, Dhayat N, Mohebbi N, Wagner CA, Cheval L, Neuhaus TJ, **Fuster DG**. Acute regulated expression of pendrin in human urinary exosomes.
Pflugers Arch. 2018;470(2):427-438.

25. Pathare G, Dhayat NA, Mohebbi N, Wagner CA, Bobulescu IA, Moe OW, **Fuster DG**. Changes in V-ATPase subunits of human urinary exosomes reflect the renal response to acute acid/alkali loading and the defects in distal renal tubular acidosis. *Kidney Int.* 2018;93(4):871-880.
26. Pathare G, Anderegg M, Albano G, Lang F, **Fuster DG**. Elevated FGF23 Levels in Mice Lacking the Thiazide-Sensitive NaCl cotransporter (NCC). *Sci Rep.* 2018;8(1):3590.
27. Dhayat NA, Lüthi D, Schneider L, Mattmann C, Vogt B, **Fuster DG**. Distinct phenotype of kidney stone formers with renal phosphate leak. *Nephrol Dial Transplant.* 2019;34(1):129-137.
28. Alexander RT, McArthur E, Jandoc R, Welk B, **Fuster DG**, Garg AX, Quinn RR. Thiazide Diuretic Dose and Risk of Kidney Stones in Older Adults: A Retrospective Cohort Study. *Can J Kidney Health Dis.* 2018;5:2054358118787480.
29. Wiegand A, Fischer G, Seeger H, Fankhauser CD, **Fuster DG**, Dhayat N, Bonny O, Hernandez T, Kim MJ, Wagner CA, Mohebbi N. Impact of potassium citrate on urinary risk profile, glucose and lipid metabolism of kidney stone formers in Switzerland *Clin Kidney J.* 2019;13(6):1037-1048.
30. Dhayat NA, Faller N, Bonny O, Mohebbi N, Ritter A, Pellegrini L, Bedino G, Schönholzer C, Venzin RM, Hüsler C, Koneth I, Del Giorno R, Gabutti L, Amico P, Mayr M, Odermatt U, Buchkremer F, Hernandez T, Stoermann-Chopard C, Teta D, Rintelen F, Roumet M, Irincheeva I, Trelle S, Tamò L, Roth B, Vogt B, **Fuster DG**. Efficacy of standard and low dose hydrochloro-thiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial. *BMC Nephrol.* 2018;19(1):349.
31. Gyimesi G, Albano G, **Fuster DG**, Hediger MA, Pujol-Giménez J. Unraveling the structural elements of pH sensitivity and substrate binding in the human zinc transporter SLC39A2 (ZIP2). *J Biol Chem.* 2019 May;294(20):8046-8063.
32. Stergachis AB, Pujol-Giménez J, Gyimesi G, **Fuster DG**, Albano G, Troxler M, Picker J, Rosenberg PA, Bergin A, Peters J, Moufawad El Achkar C, Harini C, Manzi S, Rotenberg A, Hediger MA, Rodan LH. Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism. *Ann Neurol.* 2019;85(6):921-926.
33. Dhayat NA, Pruijm M, Ponte B, Ackermann D, Leichtle AB, Devuyst O, Ehret G, Guessous I, Pechère-Bertschi A, Pastor J, Martin PY, Burnier M, Fiedler GM, Vogt B, Moe OW, Bochud M, **Fuster DG**. Parathyroid hormone and plasma phosphate are predictors of soluble α -klotho levels in adults of European descent. *J Clin Endocrinol Metab.* 2020;105(4):e1135-43.
34. Anderegg MA, Dhayat NA, Sommer G, Semmo M, Huynh-Do U, Vogt B, **Fuster DG**. Quality of life in ADPKD patients treated with Tolvaptan. *Kidney Med.* 2020; 2(2):162-171.
35. Kucharava K, Brand Y, Albano G, Sekulic-Jablanovic M, Glutz A, Xian X, Herz J, Bodmer D, Petkovic V, **Fuster DG**. Sodium-hydrogen exchanger 6 (NHE6) deficiency leads to hearing loss, via reduced endosomal signalling through the BDNF/Trk pathway. *Sci Rep.* 2020;10(1):3609.
36. Olinger E, Hofmann P, Kidd K, Dufour I, Belge H, Schaeffer C, Kipp A, Bonny O, Deltas C, Demoulin N, Fehr T, **Fuster DG**, Gale DP, Goffin E, Hodanova K, Huynh-Do U, Kistler AD, Morelle J, Papagregoriou G, Pirson Y, Sandford R, Sayer JA, Torra

- R, Venzin C, Venzin R, Vogt B, Živná M, Greka A, Dahan K, Rampoldi L, Kmoč S, Bleyer AJ Sr, Devuyst O. Clinical and Genetic Spectra of Autosomal Dominant Tubulointerstitial Kidney Disease due to Mutations in UMOD and MUC1. *Kidney Int.* 2020;98(3):717-731.
37. Bargagli M, Dhayat NA, Anderegg M, Semmo M, Huynh-Do U, Vogt B, Ferraro PM, **Fuster DG**. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan. *Clin J Am Soc Nephrol.* 2020;15(7):1007-1014.
 38. Tsaturyan A, Bokova E, Bosshard P, Bonny O, **Fuster DG**, Roth B. Oral chemolysis is an effective, non-invasive therapy for urinary stones suspected of uric acid content. *Urolithiasis.* 2020;48(6):501-507.
 39. **Fuster DG**, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, Dhayat NA. Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers. *Nephrol Dial Transplant.* 2022 Jan 25;37(2):335-348.
 40. Anderegg MA, Albano G, Hanke D, Deisl C, Uehlinger DE, Brandt S, Bhardwaj R, Hediger MA, **Fuster DG**. The Na⁺/H⁺ exchanger NHA2 regulates blood pressure through a WNK4-NCC dependent pathway in the kidney. *Kidney Int.* 2021;99(2):350-363.
 41. Verouti SN, Lambert D, Mathis D, Pathare G, Escher G, Vogt B, **Fuster DG**. The solute carrier SLC16A12 is critical for creatine and guanidinoacetate handling in the kidney. *Am J Physiol Renal Physiol.* 2021;320(3):F351-F358.
 42. Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, Deschênes P, Shasha-Lavsky H, Saland JM, van’t Hoff WG, **Fuster DG**, Magen D, Mochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnav AK, Gansner JM, McGregor TL, Lieske JC. Phase 3 Trial of Lumasiran, an RNAi Therapeutic for PH1. *N Engl J Med* 2021;384:1216-26.
 43. Bargagli M, Ferraro PM, Dhayat N, Anderegg M, **Fuster DG**. Effect of Tolvaptan treatment on acid-base homeostasis in ADPKD patients. *Kidney Int Rep.* 2021 Apr 28;6(6):1749.
 44. Schnyder D, Albano G, Kucharczyk P, Dolder S, Siegrist M, Anderegg M, Pathare G, Hofstetter W, Baron R, **Fuster DG**. Deletion of the sodium / hydrogen exchanger 6 causes increased sclerostin expression with low bone volume. *Bone.* 2021 Dec;153:116178. doi: 10.1016/j.bone.2021.116178. Epub 2021 Sep 8.
 45. Dhayat NA, Schneider L, Popp AW, Lüthi D, Mattmann C, Vogt B, **Fuster DG**. Predictors of Bone Mineral Density in Kidney Stone Formers. *Kidney Int Rep.* 2021 Dec 15;7(3):558-567.
 46. Schietzel S, Bally L, Cereghetti G, Faller N, Matthias B Moor, Vogt B, Rintelen F, Trelle S, **Fuster DG**. Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial. *BMJ Open.* 2022 Mar 14;12(3):e059073.
 47. Sekulic-Jablanovic M, Paproth J, Sgambato C, Albano G, **Fuster DG**, Bodmer D and Petkovic V. Lack of NHE6 and inhibition of NKCC1 associated with increased permeability in blood labyrinth barrier-derived endothelial cell layer. *Front Cell Neurosci.* 2022 Apr 12;16:862119.
 48. Moor MB, Dhayat NA, Schietzel S, Grössl M, Vogt B, **Fuster DG**. Urinary tetrahydroaldosterone is associated with circulating FGF23 in kidney stone formers.

- Urolithiasis*. 2022 Jun;50(3):333-340.
49. Verouti SN, Gimenez JP, Bermudez Lekerika P, Scherler L, Bhardwaj R, Thomas A, Lenglet S, Siegrist M, Hofstetter W, **Fuster DG**, Hediger MA, Escher G, Vogt B. The allelic variant of metal ion transporter ZIP8 A391T leads to reduced arterial blood pressure, renal tubular acidosis and enhanced insulin sensitivity in mouse model. *Front. Physiol.* 2022 Jun 15;13:912277. doi: 10.3389/fphys.2022.912277.
 50. Augustynek B, Gyimesi G, Dergič J, Sallinger M, Albano G, Klesse GJ, Kandasamy P, Grabmayr H, Frischauf I, **Fuster DG**, Peinelt C, Hediger MA, Bhardwaj R. Discovery of novel gating checkpoints in the Orai1 calcium channel by systematic analysis of constitutively active mutants of its paralogs and orthologs. *Cell Calcium.* 2022 Jul;105:102616. doi: 10.1016/j.ceca.2022.102616.
 51. Olinger E, Schaeffer C, Kidd K, Elhassan EA, Cheng Y, Dufour I, Schiano G, Mabillard H, Pasqualetto E, Hofmann P, **Fuster DG**, Kistler AD, Wilson IA, Kmoch S, Raymond L, Robert T, Genomics England Research Consortium, Eckardt K, Bleyer AJ, Köttgen A, Conlon PJ, Wiesener M, Sayer JA, Rampoldi L, Devuyst O. An intermediate effect size variant in UMOD confers risk for chronic kidney disease. *Proc Natl Acad Sci U S A.* 2022 Aug 16;119(33):e2114734119. doi: 10.1073/pnas.2114734119.
 52. Bargagli M, Vetsch A, Anderegg MA, Dhayat NA, Huynh-Do U, Faller N, Vogt B, Ferraro PM, **Fuster DG**. Tolvaptan treatment is associated with increased bone mineral density in ADPKD patients. *Nephrol Dial Transplant.* 2022 Oct 29;gfac298. doi: 10.1093/ndt/gfac298.
 53. Ferraro PM, Bargagli M, Faller N, Anderegg MA, Huynh-Do U, Vogt B, Gambaro G, **Fuster DG**. The role of urinary supersaturations for lithogenic salts in the progression of autosomal dominant polycystic kidney disease. *J Nephrol.* 2022 Dec 17. doi: 10.1007/s40620-022-01540-5.
 54. Mueller L, Moser M, Prazak J, **Fuster DG**, Scheffold JC, Zuercher P. Metformin's Role in Hyperlactatemia and Lactic Acidosis in ICU Patients: A Systematic Review. *Pharmacology.* 2023 Jan 18:1-11. doi: 10.1159/000528252.
 55. Bonny O, **Fuster DG**, Seeger H, Hernandez T, Buchkremer F, Wuerzner G, Dhayat N, Ritter A, Stoermann C, Segerer S, Häusermann T, Pasch A, Kim M, Mayr M, Krapf R, Roth B, Bochud M, Mohebbi N, Wagner C.A. The Swiss Kidney Stone Cohort (SKSC), a longitudinal, multi-centric, observational cohort to study course and causes of kidney stone disease in Switzerland. *Kidney Blood Press Res* 2023;0:1–8. doi: 10.1159/000529094
 56. Dhayat NA, Bonny O, Roth B, Christe A, Ritter A, Mohebbi N, Faller N, Pellegrini L, Bedino G, Venzin RM, Grosse P, Hüsler C, Koneth I, Bucher C, Del Giorno R, Gabutti L, Mayr M, Odermatt U, Buchkremer F, Hernandez T, Stoermann-Chopard C, Teta D, Vogt B, Roumet M, Tamò L, Cereghetti G, Trelle S, **Fuster DG**. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence. *N Engl J Med.* 2023 Mar 2;388(9):781-791. doi: 10.1056/NEJMoa2209275.
 57. Kucharczyk P, Albano G, Deisl C, Ho TM, Bargagli M, Anderegg M, Wueest S, Konrad D, **Fuster DG**. Thiazides attenuate insulin secretion through inhibition of mitochondrial carbonic anhydrase 5b in β -islet cells in mice. *J Am Soc Nephrol.* 2023 Mar 17. doi: 10.1681/ASN.000000000000122.

Review articles

1. Moe OW, **Fuster D**. Clinical acid-base pathophysiology: disorders of plasma anion gap. *Best Pract Res Clin Endocrinol Metab.* 2003;17(4): 559-74.

2. Hilgemann DW, Yaradanakul A, **Fuster D**. Molecular control of cardiac sodium homeostasis in health and disease.
J Cardiovasc Electrophysiol. 2006;17(5):S47-S56.
3. **Fuster D**. Pathophysiology and diagnosis of nephrocalcinosis.
Ther Umsch. 2007;64(5):287-90.
4. **Fuster D**. When do combinations of diuretics make sense ?
Ther Umsch. 2009;66(11):725-9.
5. Donowitz M, Tse M, **Fuster DG**. SLC9 or NHE Gene Family, a Plasma Membrane and Organellar Family of Na⁺/H⁺ Antiporters
Molecular Aspects of Medicine. 2013;34:236-51.
6. Serra AL, Bonny O, Bürki S, Dorn T, **Fuster DG**, Guzman R, Hofbauer G, Jenny B, Kätterer C, Plecko-Startinij B, Weibelg L, Roth, Steinlin M, Wohlraj G, Dill PE. Tuberoöse Sklerose: Pathogenese, Klinik und neue Therapieansätze
Swiss Medical Forum. 2013;13(36):696–702.
7. **Fuster DG**, Alexander RT. Traditional and emerging roles for the SLC9 Na⁺/H⁺ exchangers.
Pflugers Arch. 2014;466(1):61-76.
8. Deisl C, Albano G, **Fuster DG**. Role of Na/H Exchange in Insulin Secretion by Islet Cells.
Curr Opin Nephrol Hypertens. 2014;23(4):406-10.
9. Kistler A, Bonny O, **Fuster DG**, Martin PY, Devuyst O. Zulassung von Tolvaptan in der Schweiz bei ADPKD. Clinical Physiology of the Kidney, Electrolytes and Lithiasis. The “old” meets the “new”.
Swiss Medical Forum. 2017;17(14):336–339.
10. **Fuster DG**. Säure-Basenstörungen und Nierensteine.
Der Nephrologe. 2018;13: 30–36.
11. **Fuster DG**. Antihypertensive medication and risk of kidney stones: a Canadian wake-up call.
Hypertens Res. 2017;40(9):807-808.
12. **Fuster DG**, Moe OW. Incomplete distal renal tubular acidosis and kidney stones.
Adv Chronic Kidney Dis. 2018;25(4):366-374.
13. Faller N, Dhayat NA, **Fuster DG**. Nephrolithiasis secondary to inherited defects in the thick ascending loop of Henle and connecting tubules.
Urolithiasis. 2019;47(1):43-56.
14. Ferraro PM, Arrabal-Polo MÁ, Capasso G, Croppi E, Cupisti A, Hernandez T, **Fuster DG**, Galan JA, Grases F, Hoorn EJ, Knauf F, Letavernier E, Mohebbi N, Mochhala S, Petkova K, Pozdzik A, Sayer J, Seitz C, Strazzullo P, Trinchieri A, Vezzoli G, Vitale C, Vogt L, Unwin RJ, Bonny O, Gambaro G. A preliminary survey of practice patterns across several European kidney stone centers and a call for action in developing shared practice.
Urolithiasis. 2019;47(3):219-224.
15. Ferraro PM, **Fuster DG**. Clinical Physiology of the Kidney, Electrolytes and Lithiasis. The “old” meets the “new”.
J Nephrol. 2021;34(1):29-30.
16. **Fuster FG**. Recurrence prevention of kidney stones - pharmacologic and dietary measures.
Ther Umsch. 2021 Jun;78(5):241-246.

17. Bargagli M, Arena M, Naticchia A, Gambaro G, Mazzaferro S, Ferraro PM, **Fuster DG**. The role of diet in bone and mineral metabolism and secondary hyperparathyroidism. *Nutrients*. 2021 Jul 7;13(7):2328.
18. Alexander RT, **Fuster DG**, Dimke H. Mechanisms underlying calcium nephrolithiasis. *Annu Rev Physiol*. 2022 Feb 10;84:559-583.
19. Anderegg MA, Gyimesi G, Ho TM, Hediger MA, **Fuster DG**. The less well-known little brothers: the SLC9B / NHA sodium / proton exchanger subfamily – structure, function, regulation and potential drug-target approaches. *Front. Physiol*. 2022 May 25;13:898508. doi:10.3389/fphys.2022.898508.
20. Ho TM, Berger S, Müller P, Simonin C, Reymond JL, von Ballmoos C, **Fuster DG**. Physiological and Molecular Function of the Sodium/Hydrogen Exchanger NHA2 (SLC9B2). *Chimia*. 2022;76(12):1019-1024. doi:10.2533/chimia.2022.1019.

Other articles

Case reports

1. **Fuster D**, Frey FJ, Ferrari P. Bedrohliche Hyperkaliämie als Folge der neuen Behandlungsstrategien der Herzinsuffizienz. *Schweiz Rundsch Med Prax*. 2000; 89(49): 2073-6.
2. Röthlisberger S, Perren A, Janzen J, **Fuster D**. Bilaterale testikuläre Tumoren beim adrenogenitalen Syndrom. *Swiss Medical Forum*. 2011; 6:108-109.
3. Arampatzis S, **Fuster DG**. Gangrene and osteolysis in pancreatic insufficiency. *Kidney Int*. 2012; 82(3):364.
4. Haeberlin A, **Fuster DG**. Abdominal pain, emesis and dyspnea after kidney transplantation. *Nephrology*. 2015;20(8):582-3.
5. Schietzel S, Moor MB, **Fuster DG**. Severe Hypomagnesemia. *J Nephrol*. 2021; doi: 10.1007/s40620-021-01001-5.
6. Harmacek D, Becker D, Bühlmann R, Lyttwin B, **Fuster DG**. Ungewöhnliche Ursache einer ausgeprägten Proteinurie. *Swiss Medical Forum*. 2021;21(27-28):491-494.
7. Anderegg M, Liu M, Saganas C, Montani M, Vogt B, Hunyh-Do U, **Fuster DG**. De novo vasculitis after mRNA-1273 (Moderna) vaccination. *Kidney Int*. 2021 Aug;100(2):474-476.

Book chapters

1. Moe OW, **Fuster D**, Alpern RJ. Common acid-base disorders. *Hospital Medicine*. 2nd edition 2003.
2. **Fuster DG**, Moe OW. Renal tubular acidosis and urolithiasis. *Kidney Stones: Medical and Surgical Management*. 2nd edition 2019.
3. **Fuster DG**, Deisl C, Hilgemann D, Moe OW. Na⁺/H⁺ Exchange. *Seldin and Giebisch - The Kidney: Physiology and Pathophysiology* 6th edition, in press.

Conference articles

1. Gambaro G, Croppi E, Coe F, Lingeman J, Moe OW, Worchester W, Buchholz N, Bushinsky D, Curhan G, Ferraro PM, **Fuster DG**, Goldfarb D, Pfeferman-Heilberg I, Hess B, Lieske J, Marangella M, Milliner D, Preminger G, Reis Santos JM, Sakhaee K, Sarcia K, Siener R, Strazullo P, Williams J. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.
J Nephrol. 2016;29(6):715-734.
2. Williams JC, Gambaro G, Rodgers A, Asplin J, Bonny O, Costa-Bauzá A, Ferraro PM, Fogazzi GB, **Fuster DG**, Goldfarb DS, Grases F, Heilberg IP, Kok D, Letavernier E, Lippi G, Marangella M, Nouvenne A, Petrarulo M, Siener R, Tiselius HG, Traxer O, Trinchieri A, Croppi E, and Robertson WG. Urine and Stone Analysis for the Investigation of the Renal Stone Former: A Consensus Conference.
Urolithiasis. 2021;49(1):1-16.